|1.||Xie, Jianping: 3 articles (06/2014 - 10/2011)|
|2.||Blasi, Paolo: 3 articles (01/2014 - 01/2010)|
|3.||Giovagnoli, Stefano: 3 articles (01/2014 - 01/2010)|
|4.||Ricci, Maurizio: 3 articles (01/2014 - 01/2010)|
|5.||Plikaytis, Bonnie B: 3 articles (04/2013 - 02/2005)|
|6.||Shinnick, Thomas M: 3 articles (04/2013 - 02/2005)|
|7.||Palmero, Domingo: 2 articles (10/2015 - 07/2013)|
|8.||Pillay, Manormoney: 2 articles (08/2015 - 01/2013)|
|9.||Crudu, V: 2 articles (04/2015 - 02/2014)|
|10.||Rodwell, T C: 2 articles (04/2015 - 02/2014)|
01/01/1966 - "[Clinical study on the therapy of pulmonary tuberculosis with Capreomycin]."
09/01/1964 - "TREATMENT OF PULMONARY TUBERCULOSIS BY CAPREOMYCIN AND PAS: A SMALL PRELIMINARY TRIAL."
04/01/2013 - "Capreomycin supergenerics for pulmonary tuberculosis treatment: preparation, in vitro, and in vivo characterization."
08/01/2010 - "A patient of multidrug-resistant pulmonary tuberculosis was prescribed an anti-tubercular regimen containing capreomycin. "
01/01/1970 - "Combination treatment with capreomycin of pretreated cavernous pulmonary tuberculosis."
10/16/1964 - "CAPREOMYCIN: ACTIVITY AGAINST EXPERIMENTAL INFECTION WITH MYCOBACTERIUM LEPRAE."
07/01/2012 - "Intrapulmonary aerosol delivery of isoniazid, capreomycin, and amikacin to mice with pulmonary infection of Mycobacterium tuberculosis demonstrated efficacy in reducing pulmonary bacterial loads similar to that seen by standard drug delivery methods, even when lower concentrations of drugs and fewer doses were used in the aerosolized drug regimens. "
01/01/2015 - "Capreomycin, levofloxacin and moxifloxacin emerged as promising candidates for the treatment of RGM infections, and cefoxitin and meropenem were active against most strains. "
01/01/2014 - "The aim of this work was to characterize novel palladium (Pd) complexes with second-line antitubercular drugs, namely capreomycin (C), kanamycin (K) and ofloxacin (Ofx), and to address the in vitro extracellular and intracellular activity against Mycobacterium tuberculosis infection. "
01/01/2014 - "tuberculosis, increases the MIC of capreomycin. "
10/01/2011 - "tuberculosis might be the new targets of CPM beyond Rv1364c, pe_pgrs38, pe_pgrs51 which are the salient nodes of the network and represent most promising new capreomycin targets meriting further exploration. "
10/01/2011 - "tuberculosis genes response to capreomycin. "
06/01/2011 - "tuberculosis, as mutations in this gene are infrequent and not all mutations in tlyA lead to capreomycin resistance."
08/01/2007 - "Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model."
|4.||Extensively Drug-Resistant Tuberculosis
08/15/2015 - "We performed this study to assess the prevalence, clinical significance, and molecular epidemiology of capreomycin resistance in newly diagnosed patients with XDR-TB in KwaZulu-Natal, South Africa. "
08/15/2015 - "Capreomycin should be included in routine DST in all patients with XDR-TB. "
08/15/2015 - "Capreomycin resistance is common in patients with XDR-TB in KwaZulu-Natal, is predominantly because of ongoing province-wide transmission of a highly resistant strain, and is associated with high mortality. "
08/15/2015 - "A total of 47/52 (90.4%) patients with XDR-TB were capreomycin resistant. "
08/15/2015 - "Drug-susceptibility testing (DST) for capreomycin is not routinely performed in newly diagnosed XDR-TB in South Africa. "
|5.||Multidrug-Resistant Tuberculosis (Drug-Resistant Tuberculosis)
06/01/2013 - "Phase I, single-dose, dose-escalating study of inhaled dry powder capreomycin: a new approach to therapy of drug-resistant tuberculosis."
07/10/2015 - "Capreomycin sulfate (CS) is a second-line drug used for the treatment of multidrug-resistant tuberculosis (MDR-TB). "
06/01/2014 - "Capreomycin (CAP) is an important second-line drug for multidrug-resistant tuberculosis. "
01/01/2014 - "Capreomycin is a second-line drug for multiple-drug-resistant tuberculosis (TB). "
08/01/2007 - "Capreomycin is used for the treatment of multidrug-resistant tuberculosis (MDR-TB), but it is limited therapeutically by its severe side effects. "
|7.||Aminosalicylic Acid (Rezipas)
|2.||Drug Therapy (Chemotherapy)
|4.||Respiratory Therapy (Therapy, Respiratory)